Squamous cell carcinoma, Bristol-Myers Squibb, Lung cancer, Carcinoma, Cancer, Squamous epithelium
Gen 2: Berkeley spinout lands $175M megaround to keep it on the cutting edge of the booming gene-editing field
The big bucks keep pumping into the gene-editing field. This morning Metagenomi, allied with one of the biggest names in the mRNA field with a company DNA that includes the ubiquitous Jennifer Doudna, is showing off a $175 million B round that will pay for a rapid swelling of its
Gen 2: Berkeley spinout lands $175M megaround to keep it on the cutting edge of the booming gene-editing field
The big bucks keep pumping into the gene-editing field. This morning Metagenomi, allied with one of the biggest names in the mRNA field with a company DNA that includes the ubiquitous ...
We are sorry, we could not find the related article
If you are curious about Biotech Essentials and Career and Jobs
Please click on:
Subscribe to Biotech Essentials - Career and Jobs
A new cancer immunotherapy brings cautious hope for a field long awaiting the next big breakthrough
Bob Seibert sat silent across from his daughter at their favorite Spanish restaurant near his home in Charleston County, SC, their paella growing cold as he read through all the places in ...
Nektar lifted by Merck alliance for bempeg, new trial funding
Three way deal between Merck, Nektar and Blackstone/Abingworth’s SFJ Pharma will see bempegaldesleukin (NKTR-214) paired with Keytruda in first-line head and neck cancer
Sutro Biopharma to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the ...
FDA demands for data from Incyte as it rejects PD-1 retifanlimab for approval
Incyte snuck out some bad news Friday night: Afterhours, the Wilmington, Delaware-based biopharma said it had been hit with an FDA complete response letter for its experimental checkpoint ...
Biopharma News You've Missed This Week
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
TARRYTOWN, N.Y. and PARIS , April 27, 2020 /PRNewswire/ -- Libtayo decreased the risk of death by 32.4% compared to chemotherapy Regeneron and Sanofi plan regulatory submissions in 2020 ...
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
Results from two studies of BAVENCIO® to be featured in ASCO press briefingPrimary efficacy, biomarker and HRQoL analyses for tepotinib†, the first MET inhibitor to have received ...
Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma
In the trial, the objective response rate (ORR) for patients (n=84) with locally advanced disease was 29% (95% CI: 19%-40%), with an estimated duration of response (DOR) exceeding one year ...
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Hematology/Oncology (Cancer) Approvals & Safety Notifications